Physician
Vivid Pathology PA
Vivid Pathology PA was paid $591K by Medicaid between Jan 2018 and Nov 2024, across 106 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 23% of everything it billed.
33Billing provider infoVIVID PATHOLOGY PA
PENSACOLA, FL 32503
PENSACOLA, FL 32503
33aNPI1447227590assigned 03/07/2006
33bProvider typeCytopathology Physician
28Total paid$591K
24GClaims240,638
24DCodes billed106
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Cytopathology Physician providers in Florida
Rank by total paid#9 of 14
Median peer was paid$776K
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 57,198 | $70K | |
| 2019 | 62,293 | $137K | |
| 2020 | 54,674 | $116K | |
| 2021 | 39,490 | $136K | |
| 2022 | 25,456 | $83K | |
| 2023 | 1,001 | $30K | |
| 2024incomplete | 526 | $19K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 23% | 4,470 | 3,617 | $136K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 19% | 3,853 | 3,404 | $110K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 12% | 6,644 | 5,834 | $74K |
| 88307 | 6.9% | 981 | 782 | $41K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 5.6% | 735 | 686 | $33K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.6% | 1,446 | 1,154 | $27K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 3.4% | 3,806 | 3,360 | $20K |
| 88141 | 3.4% | 1,917 | 1,703 | $20K | |
| 88304 | 2.8% | 1,005 | 851 | $17K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2.6% | 683 | 613 | $15K |
| 80053 | Comprehensive metabolic panel | 2.5% | 26,652 | 15,583 | $15K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 2.0% | 1,900 | 1,641 | $12K |
94 more codes
| 81513 | 1.8% | 271 | $11K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 41,151 | $10K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.3% | 14,943 | $8K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.1% | 580 | $7K |
| 88342 | <1% | 174 | $4K | |
| 87481 | <1% | 192 | $4K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,334 | $4K |
| 81001 | <1% | 14,050 | $2K | |
| 84703 | <1% | 4,595 | $2K | |
| 87040 | <1% | 2,367 | $2K | |
| 83735 | <1% | 10,109 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,548 | $2K |
| 83690 | <1% | 4,919 | $1K | |
| 86803 | <1% | 1,292 | $1K | |
| 83605 | <1% | 2,182 | $1K | |
| 84484 | <1% | 4,035 | $975.54 | |
| 80061 | Lipid panel | <1% | 1,405 | $860.59 |
| 85610 | <1% | 3,821 | $762.12 | |
| 82805 | <1% | 2,985 | $711.90 | |
| 82330 | <1% | 964 | $643.31 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,213 | $631.14 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,063 | $550.92 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 999 | $532.78 |
| 87077 | <1% | 1,378 | $530.81 | |
| 87486 | <1% | 847 | $512.14 | |
| 82962 | <1% | 9,144 | $504.67 | |
| 87581 | <1% | 849 | $471.80 | |
| 86850 | <1% | 3,622 | $411.84 | |
| 85027 | <1% | 4,809 | $384.14 | |
| 82247 | <1% | 1,989 | $322.11 | |
| 86900 | <1% | 6,155 | $301.49 | |
| 86901 | <1% | 6,238 | $300.67 | |
| 87186 | <1% | 658 | $279.08 | |
| 87340 | <1% | 1,416 | $258.86 | |
| 87210 | <1% | 930 | $252.84 | |
| 82550 | <1% | 478 | $246.63 | |
| 87070 | <1% | 427 | $200.56 | |
| 82950 | <1% | 1,108 | $194.16 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 412 | $189.54 |
| 86592 | <1% | 1,965 | $181.36 | |
| 86762 | <1% | 819 | $152.56 | |
| 81003 | <1% | 1,113 | $151.20 | |
| 80076 | <1% | 2,142 | $139.37 | |
| 87205 | <1% | 669 | $132.96 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 87 | $110.38 |
| 85730 | <1% | 1,658 | $92.56 | |
| 85060 | <1% | 35 | $84.75 | |
| 82150 | <1% | 152 | $77.17 | |
| 86140 | <1% | 2,635 | $77.04 | |
| 82553 | <1% | 692 | $77.00 | |
| 82570 | <1% | 489 | $68.13 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 45 | $63.52 |
| 82947 | <1% | 300 | $39.54 | |
| 82375 | <1% | 2,186 | $36.13 | |
| 84702 | <1% | 999 | $31.80 | |
| 86880 | <1% | 862 | $31.75 | |
| 84466 | <1% | 63 | $26.74 | |
| 82607 | <1% | 219 | $26.73 | |
| 87641 | <1% | 27 | $26.25 | |
| 82728 | <1% | 318 | $22.71 | |
| 84439 | <1% | 753 | $22.58 | |
| 84480 | <1% | 27 | $21.00 | |
| 83615 | <1% | 1,237 | $16.20 | |
| 87081 | <1% | 262 | $15.33 | |
| 83050 | <1% | 2,186 | $13.97 | |
| 85018 | <1% | 150 | $12.36 | |
| 82565 | <1% | 175 | $12.22 | |
| 84436 | <1% | 12 | $10.08 | |
| 82248 | <1% | 919 | $8.76 | |
| 87075 | <1% | 18 | $8.55 | |
| 82040 | <1% | 66 | $6.96 | |
| 82435 | <1% | 54 | $0.81 | |
| 84550 | <1% | 16 | $0.65 | |
| 84156 | 0% | 400 | $0.00 | |
| 85045 | 0% | 320 | $0.00 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 284 | $0.00 |
| 84295 | 0% | 53 | $0.00 | |
| 83540 | 0% | 99 | $0.00 | |
| 82140 | 0% | 45 | $0.00 | |
| 80074 | 0% | 43 | $0.00 | |
| 84100 | 0% | 30 | $0.00 | |
| G9785 | Pathology report diagnosing cutaneous basal cell carcinoma, squamous cell carcinoma, or melanoma (to include in situ disease) sent from the pathologist/ dermatopathologist to the biopsying clinician for review within 7 days from the time when the tissue specimen was received by the pathologist | 0% | 14 | $0.00 |
| 84145 | 0% | 35 | $0.00 | |
| 87653 | 0% | 17 | $0.00 | |
| 83525 | 0% | 36 | $0.00 | |
| 85384 | 0% | 26 | $0.00 | |
| 84132 | 0% | 37 | $0.00 | |
| 86920 | 0% | 246 | $0.00 | |
| 85652 | 0% | 540 | $0.00 | |
| 85379 | 0% | 143 | $0.00 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 0% | 24 | $0.00 |
| 82746 | 0% | 25 | $0.00 | |
| 80050 | General health panel | 0% | 85 | $0.00 |
| 82378 | 0% | 42 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDADISMAN, CHRISTOPHER (PRESIDENT)